Stay up to date and read the latest news about Wellington Partners and the Wellington Partners portfolio.

Filter Categories
Show all
Portfolio News
Wellington Partners
  • 8. April 2024
    MMI Receives FDA Authorization to Commercialize Symani® Surgical System in the U.S.
  • 5. April 2024
    ONWARD® Medical Submits De Novo Application to FDA for its ARC-EX® System
  • 1. April 2024
    Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
  • 1. April 2024
    Carisma Therapeutics Announces Changes to its Board of Directors
  • 26. March 2024
    TRiCares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer
  • 14. March 2024
    Bayer and Aignostics to collaborate on next generation precision oncology
  • 21. February 2024
    MMI Raises $110 Million in Series C Financing
  • 15. February 2024
    UroMems Announces Results of First-Ever Smart Artificial Urinary Sphincter Implant in Female Patient to Treat Stress Urinary Incontinence
  • 18. January 2024
    eGenesis and OrganOx Announce Successful Use of a Genetically Engineered Porcine Liver with a Human Donor
  • 14. December 2023
    First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
  • 13. December 2023
    UroMems Reaches Significant Milestone: Successful Results in Clinical Feasibility Study of UroActive™ Smart Implant for Stress Urinary Incontinence Treatment
  • 8. November 2023
    Nature Medicine Publication Highlights Potential for ONWARD® ARC Therapy™ to Improve Mobility After Parkinson’s Disease
  • 6. November 2023
    Wellington Partners promotes Johannes Fischer and Varun Gupta to Partner
  • 31. October 2023
    Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC
  • 25. October 2023
    Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023
  • 24. October 2023
    Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
  • 11. October 2023
    MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus
  • 11. October 2023
    Sidekick Health announces landmark acquisition, expanding its portfolio to offer regulated Prescription Digital Therapeutics
  • 11. October 2023
    eGenesis Announces Publication in Nature of Landmark Preclinical Data Demonstrating Long-Term Survival with Genetically Engineered Porcine Kidneys
  • 25. September 2023
    4SC: Landmark RESMAIN study data presented at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting
  • 11. September 2023
    Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
  • 30. August 2023
    Confo Therapeutics Appoints Dieter Weinand, Former CEO of Bayer Pharmaceuticals, as Independent Chairman
  • 23. August 2023
    Quanta™ Announces Enrollment Completion in Home Run Study
  • 10. August 2023
    Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
  • 4. August 2023
    Quanta™ Receives FDA 510(k) Clearance for Expanded Indication of Continuous Renal Replacement Therapies
  • 31. July 2023
    BioM-Podcast: "In der Frühphase, in der Forschung sind wir Weltmeister"
  • 24. July 2023
    Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
  • 29. June 2023
    Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors
  • 22. June 2023
    nyra health raises €4.5m Seed Round to advance its digital neuro-therapy
  • 31. May 2023
    Resminostat: 4SC Filed Letter of Intent to the European Medicines Agency (EMA)
  • 25. May 2023
    Brain Computer Interface (BCI) Enables Thought-Controlled Walking after Spinal Cord Injury
  • 25. May 2023
    4SC AG – RESMAIN Trial Meets Primary Endpoint in Cutaneous T-Cell Lymphoma (CTCL)
  • 4. May 2023
    Upon FDA approval, Advanced Medical Balloons launches innovative hygh-tec catheter system for ICU stool drainage in U.S. market
  • 2. May 2023
    Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
  • 21. April 2023
    UroMems Granted Safer Technologies Program Designation from FDA for Smart Implant to Treat Stress Urinary Incontinence
  • 17. April 2023
    MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults
  • 3. April 2023
    Sidekick Health chosen as partner for White House’s CancerX project to rapidly accelerate the pace of cancer innovation in the U.S.
  • 30. March 2023
    Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases
  • 23. March 2023
    ImCheck Appoints Thomas Civik as Independent Chairman of the Board
  • 16. March 2023
    Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases
  • 8. March 2023
    Carisma Therapeutics Closes Merger with Sesen Bio
  • 2. March 2023
    Confo Therapeutics Announces Global Licensing Agreement With Lilly For Peripheral Pain Candidate, CFTX-1554
  • 5. January 2023
    MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine
  • 16. December 2022
    MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus
  • 13. December 2022
    TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation
  • 9. December 2022
    ONWARD Reports Interim Clinical Outcomes for Implantable ARC Therapy Demonstrating Potential to Improve Blood Pressure Regulation after Spinal Cord Injury
  • 29. November 2022
    UroMems Initiates First-in-Human Study of Its Smart Implant to Treat Stress Urinary Incontinence
  • 17. November 2022
    Boditech Med and SphingoTec close global licensing agreement for kidney function biomarker Proenkephalin A 119-159 (penKid)
  • 13. October 2022
    NEUWAY Pharma and WACKER Launch Research Project to Develop RNA-Based Actives for the Treatment of Central Nervous System Diseases
  • 12. October 2022
    Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME
  • 10. October 2022
    Immatics Announces $110 Million Underwritten Offering of Ordinary Shares
  • 5. October 2022
    ONWARD Announces Appointment of Vivian Riefberg to Board of Directors
  • 21. September 2022
    Sesen Bio and Carisma Therapeutics Announce Merger Agreement
  • 19. September 2022
    Aignostics Raises €14m Series A to Advance AI-powered Pathology
  • 14. September 2022
    ONWARD Reports Positive Topline Results from a Pivotal Study to Restore Arm and Hand Function in People with Spinal Cord Injury
  • 12. July 2022
    Quanta Dialysis Technologies: Team behind compact dialysis machine wins award for UK’s top engineering innovation of 2022
  • 13. June 2022
    ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline
  • 3. June 2022
    Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
  • 19. May 2022
    TRiCares Announces Successful Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Canada
  • 18. May 2022
    Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors
  • 12. May 2022
    Koa Health Partners with Virgin Pulse to Extend Mental Health Programs via VP+ Program
  • 11. May 2022
    Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors
  • 10. May 2022
    UroMems Appoints Steffen Hovard to Chairman of the Board of Directors
  • 9. May 2022
    Digital Therapeutics Leader Sidekick Raises $55M Series B To Drive Further Growth
  • 25. April 2022
    TRiCares Announces Successful First in Human Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Germany
  • 19. April 2022
    eGenesis Promotes Michael Curtis, Ph.D., to Chief Executive Officer
  • 13. April 2022
    ONWARD Announces Additions to Leadership Team
  • 11. April 2022
    PEI Regulatory Approval Received for Government Funded (€ 7.4 Million) Clinical Trial Investigating Adrenomed’s Adrecizumab in Treating Endothelial Barrier Dysfunction in Hospitalized COVID-19 Patients
  • 7. April 2022
    ONWARD Medical’s Parkinson’s Therapy Published in New England Journal of Medicine
  • 4. April 2022
    eGenesis Appoints Eliezer Katz, M.D., FACS, as Chief Medical Officer
  • 28. March 2022
    ONWARD adds new brain-spine interface and Parkinson’s disease IP to license agreements
  • 15. March 2022
    Adrenomed Supervisory Board appoints Dr. Richard Jones as CEO
  • 9. March 2022
    First participants enrolled in ONWARD’s LIFT home study
  • 7. February 2022
    ONWARD medical’s technology enables walking and standing after severe spinal cord injuries
  • 12. January 2022
    Moderna and Carisma establish collaboration to develop in vivo engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
  • 10. January 2022
    Creative Balloons appoints David Johnson as Chairman of the Board of Directors
  • 16. December 2021
    ONWARD Announces Completion of Enrollment in the Up- LIFT Pivotal Trial of ARC Therapy for Spinal Cord Injury
  • 14. December 2021
    Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
  • 7. December 2021
    ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Gamma-delta T Cells in Science Translational Medicine
  • 7. December 2021
    Confo Therapeutics Enters Collaborative Agreement With Regeneron
  • 6. October 2021
    iOmx Therapeutics raises EUR 65 million in Series B round
  • 17. September 2021
    ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
  • 26. August 2021
    TRiCares Announces Successful First in Human Implantations of Minimally Invasive Topaz Tricuspid Heart ...
  • 23. June 2021
    Quanta Raises $245 Million to Accelerate Commercialization of its SC+ Portable Hemodialysis System
  • 9. April 2021
    Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response
  • 6. April 2021
    UroMems Completes €23 Million Series B Financing
  • 18. March 2021
    Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs
  • 4. March 2021
    Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications
  • 2. March 2021
    eGenesis Announces $125 Million Series C Financing
  • 24. February 2021
    Creative Balloons closes €15 million growth financing and appoints Frank Gehres as CEO
  • 29. January 2021
    ONWARD Announces Publication in Nature Demonstrating Blood Pressure Stabilization in People with Spinal Cord Injury
  • 12. January 2021
    ONWARD Announces First Patient Enrolled in the Up-LIFT Pivotal Trial Assessing Safety and Effectiveness of ARC Therapy for Spinal Cord Injury
  • 12. January 2021
    ONWARD Completes $32 Million Financing Round
  • 8. January 2021
    Quanta Receives FDA 510(k) Clearance for the SC+ Hemodialysis System Setting the Stage for US Market Launch
  • 8. January 2021
    PerkinElmer to Acquire Oxford Immunotec Global PLC
  • 8. January 2021
    CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies
  • 8. January 2021
    CARISMA Therapeutics Appoints Richard Morris as Chief Financial Officer
  • 15. December 2020
    MinervaX raises upsized EUR 47.4M (USD 57M) Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials
  • 15. December 2020
    Adrenomed Supervisory Board appoints Dr. Wolfgang Baiker as CEO
  • 11. November 2020
    Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference
  • 5. November 2020
    Koa Health secures over €14m initial funding and spins out of Telefónica’s moonshot factory
  • 28. October 2020
    Digital therapeutics leader Sidekick raises $20M in Series A funding round led by Wellington and Asabys
  • 27. July 2020
    CARISMA Therapeutics announces FDA clearance of IND application for first-ever engineered macrophage immunotherapy
  • 2. July 2020
    Immatics announces completion of business combination and listing on NASDAQ
  • 1. July 2020
    SIRS Therapeutics: F4 Pharma’s FX06 shows promising results in critically ill COVID-19 patients
  • 10. June 2020
    Confo Therapeutics expands board with appointment of Rob Scott as Independent Director
  • 9. June 2020
    GTX Medical was granted FDA Breakthrough Device Designation for Go-2 Targeted Epidural Spinal Stimulation (TESS) system
  • 4. June 2020
    Confo Therapeutics appoints Paolo Vicini as Chief Development Officer
  • 26. May 2020
    Wellington Partners’s portfolio company Themis to be acquired by MSD
  • 14. May 2020
    Themis collaborates with ABL Europe to manufacture its SARS-CoV-2 Vaccine Candidate in France
  • 27. April 2020
    UroMems appoints medical device industry leader Steffen Hovard to Board of Directors
  • 20. April 2020
    GTX Medical appoints John Murphy as Chief Technology Officer
  • 17. April 2020
    Themis announces Iain Dukes to join the company’s supervisory board
  • 16. April 2020
    STipe Therapeutics appoints Dr Natalie Sacks as Independent Board Member and Dr Richard Bethell as Chief Development Officer
  • 15. April 2020
    Wellington invests in SIRS Therapeutics to develop FX06 for treatment of ARDS in COVID-19 patients in collaboration with F4 Pharma
  • 26. March 2020
    First patient dosed in EVICTION trial evaluating ImCheck’s lead anti-cancer drug ICT01
  • 24. March 2020
    Carisma Therapeutics: First-of-its-kind engineered macrophage cell therapy platform shows ability to reduce tumor burden & activate anti-tumor immunity, improving overall survival in pre-clinical cancer models
  • 8. January 2020
    Karl Naegler joins Wellington Partners as Managing Partner
  • 4. December 2019
    Wellington Partners participates in $53 Million Series B financing at ImCheck
  • 7. November 2019
    Wellington Partners participates in $100 Million Series B financing at eGenesis
  • 25. October 2019
    UroMems wins prestigious Prix Galien Med’Start-Up for best collaboration in the medtech or digital sector
  • 22. October 2019
    GTX medical & NeuroRecovery Technologies merge to create leading neurostimulation company for SCI
  • 1. October 2019
    Themis and ZIKAVAX consortium announce initiation of Phase 1 Zika vaccine trial
  • 30. September 2019
    STipe Therapeutics launches with EUR 20 million Series A financing
  • 30. September 2019
    iOmx Therapeutics announces discovery of novel, druggable immune-checkpoint targets
  • 30. September 2019
    AMBOSS raises €30M in Series B
  • 26. September 2019
    Adrenomed completes full enrollment with 300 patients in AdrenOSS-2 trial with Adrecizumab in septic shock
  • 23. September 2019
    FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019
  • 18. September 2019
    Themis raises EUR 40 Million in Series D financing round backed by US/EU consortium
  • 29. August 2019
    Adrenomed Supervisory Board appoints Jens Schneider-Mergener as CEO & Jens Zimmermann (CMO) joins the Executive Board
  • 28. August 2019
    Immatics and Celgene enter strategic collaboration to develop novel adoptive cell therapies
  • 22. August 2019
    Themis announces exclusive license and research collaboration agreement with MSD to develop vaccine candidates
  • 31. July 2019
    Wellington Partners raises EUR 210 million life science fund
  • 29. July 2019
    Quanta raises $48 million in Series C funding round
  • 8. July 2019
    Immatics appoints Harpreet Singh as Chief Executive Officer
  • 21. June 2019
    Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication
  • 4. June 2019
    CEPI awards up to US$21 million to Themis for Phase 3 Chikungunya Vaccine Development
  • 28. May 2019
    US patent grants strengthen SNIPR BIOME’s approach to enhance immuno-oncology outcomes by microbiome modulation
  • 7. May 2019
    Wellington Partners co-leads €30 million Series A financing in Confo Therapeutics
  • 11. March 2019
    SNIPR BIOME raises $50 million Series A financing to advance CRISPR-based microbiome drugs to human clinical trials
  • 27. February 2019
    Immatics announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers
  • 27. February 2019
    Themis receives FDA fast track designation for Chikungunya vaccine candidate
  • 7. January 2019
    AYOXXA signs research agreement in the field of ophthalmology with one of the leading pharmaceutical companies
  • 26. November 2018
    Adrenomed closes €24 million financing led by Wellington Partners and HBM
  • 6. November 2018
    Themis publishes compelling Phase 2 results for lead vaccine candidate against Chikungunya fever in "The Lancet"
  • 11. October 2018
    Themis announces exclusive licensing agreement with Max-Planck-Innovation to develop and commercialize oncolytic virotherapies
  • 9. October 2018
    Sphingotec raises €20 million from HBM and Wellington Partners
  • 6. September 2018
    Themis presents Phase II interim results for Chikungunya vaccine candidate at ASTMH 2017
  • 27. June 2018
    Carisma Therapeutics announces $53 million Series A financing
  • 4. June 2018
    TRiCares closes €22 million Series B financing round
  • 27. March 2018
    4SC: Yakult Honsha joins pivotal RESMAIN study of resminostat in CTCL
  • 6. March 2018
    CEPI partners with Themis to advance vaccines against Lassa fever and MERS
  • 26. February 2018
    Themis establishes Scientific Advisory Board of experts in virology and vaccine development
  • 1. February 2018
    Physicians at Helios gain access to Amboss platform
  • 17. January 2018
    Immatics appoints Thomas Ulmer as Chief Financial Officer
  • 4. January 2018
    Themis raises EUR 10 million in Series C financing to advance clinical pipeline
  • 25. October 2017
    Ambu acquires Wellington Partners portfolio company invendo medical
  • 4. October 2017
    Immatics receives $58 million in financing to develop T-cell receptor based immunotherapies
  • 28. September 2017
    Immatics initiates first Phase I clinical trial of ACTengine® approach in patients with advanced solid cancers
  • 8. September 2017
    Wellington featured in BioCentury
  • 6. September 2017
    MSD to acquire Rigontec
  • 5. September 2017
    Themis: Chikungunya vaccine development towards Phase III trials receives £ 3 Mio. boost by Innovate UK
  • 21. August 2017
    Immatics initiates personalized adoptive cellular therapy in patients with relapsed and/or refractory solid cancers using its pioneering target warehouse
  • 27. July 2017
    Themis starts Phase II clinical study of Chikungunya vaccine in endemic area
  • 6. July 2017
    4SC secures EUR 41 million from successful capital increase
  • 8. June 2017
    Themis starts Phase II trial of Chikungunya vaccine in the U.S.
  • 3. May 2017
    Rigontec starts FIH Phase I/II trial of RIG-I agonist RGT100 & appoints new CMO
  • 7. December 2016
    AYOXXA appoints permanent CEO
  • 5. December 2016
    invendo medical announces CE mark
  • 17. November 2016
    Chiesi Group acquires Atopix
  • 15. November 2016
    Wellington invests in Uromems
  • 14. November 2016
    Rigontec appoints new CSO
  • 7. November 2016
    Ayoxxa announces new CEO
  • 7. November 2016
    Immatics and Amgen sign $1B deal
  • 5. October 2016
    4SC: overall survival benefit for resminostat in first-line liver cancer study subgroup
  • 5. October 2016
    4SC's Resminostat shows survival benefit
  • 22. September 2016
    Wellington invests in iOmx €40m Series A
  • 13. September 2016
    Themis Zika Vaccine Developement receives 1 Mio GBP Boost
  • 13. September 2016
    Themis vector technology featured in quest for Zika vaccine by Top EU-groups
  • 13. September 2016
    Themis launches Zika vaccine clinical trial
  • 6. September 2016
    Rigontec extends Series A with additional €15 million
  • 16. June 2016
    Resminostat boosts cancer immunotherapy
  • 7. June 2016
    NEUWAY Awarded €2.95M Grant
  • 12. May 2016
    Invendo receives FDA clearance for Invendoscopy E200 System
  • 12. May 2016
    Themis announces exclusive license with Institut Pasteur and Zika vaccine
  • 12. May 2016
    Symetis acquires Middle Peak Medical
  • 12. May 2016
    Boston Scientific acquires Symetis for USD 435m in cash